Vivos Therapeutics, Inc. (VVOS): debt financing — Vivos Therapeutics enters $1.1M convertible note to fund pending SCN acquisition

Vivos Therapeutics, Inc.

$1.1M principal convertible note to V-Co Investors 2 LLC; net funding $1M after $100k fee.
Zero interest unless default; default rate 15% p.a.; secured by equipment only on default.
Converts automatically into equity of subsequent financing expected at SCN closing (target July 31, 2025).
Proceeds to fund previously announced acquisition of The Sleep Center of Nevada.
V-Co is affiliate of existing investor New Seneca Partners Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.7

Vivos Therapeutics, Inc. incurred convertible notes of $1,100,000 with V-Co Investors 2 LLC at 0% (15% per annum upon Event of Default) maturing No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date.

Instrument: convertible notes
Principal: $1,100,000
Counterparty: V-Co Investors 2 LLC
Rate: 0% (15% per annum upon Event of Default)
Maturity: No fixed maturity date; convertible prior to Outside Date or repayable after Outside Date
Event: incurrence

Exact text from the filing

On May 21, 2025, Vivos Therapeutics, Inc. (the “ Company ”) entered into a convertible promissory note in favor of V-Co Investors 2 LLC (“ V-Co ”) in the principal amount of $1,100,000 (the “ Note ”).

View on SEC.gov

Browse all debt financings →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-012181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.